No securities are beneficially owned.
In connection with the Agreement and Plan of Merger, dated as of October 17, 2022, among the reporting persons and the Issuer, the reporting persons entered into tender and support agreements, each dated as of October 17, 2022 (collectively, the "Tender and Support Agreements"), with (i) Emmanuel Simons, (ii) 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., and (iii) New Enterprise Associates 16, L.P. and NEA Ventures 2018, L.P. (collectively, the "Parties"), pursuant to which each of the Parties agreed to grant certain voting rights to Eli Lilly and Company with respect to the shares of Issuer's common stock held by each such Party (collectively, the "Shares"). As a result of the Tender and Support Agreements, each of the reporting persons may be deemed to have acquired beneficial ownership in excess of 10% of the Issuer's issued and outstanding common stock for the purpose of determining each reporting person's status as a ten percent owner thereof. However, neither of the reporting persons has a pecuniary interest in the Shares and each expressly disclaims beneficial ownership thereof. The filing of this Form 3 shall not be deemed an admission of beneficial ownership of the Shares for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.